AbbVie has finally claimed FDA approval for its ... via a percutaneous jejunostomy tube, which requires a surgical procedure to set up, so is expected to be superseded by Vyalev, which some ...

AbbVie already sells another long-acting treatment called Duopa, which delivers carbidopa and levodopa in an intestinal gel form via a gastric tube and pump ... the Michael J Fox Foundation ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

AbbVie is scheduled to report full-year earnings on Jan. 31, but management said at the J.P. Morgan Healthcare Conference last week that the company grew in fiscal year 2024 despite falling sales ...

AbbVie maintains top TV ad spend spot with Skyrizi but sees Rinvoq fall behind J&J's Tremfya, Novo's Wegovy Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Louis Navellier is a prominent American investor, author, and financial analyst ...